<p>With Covishield vaccine getting cleared by the government to combat the Covid-19 pandemic, Serum Institute of India (SII) CEO Adar Poonawalla said on Sunday that the risk they too has finally paid off.</p>.<p>"Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. Covishield, India's first Covid-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks," Poonawalla tweeted.</p>.<p>Last week, Poonawala had said that the company a stockpile of 40 to 50 million doses and the company will ramp up the capacity to 100 million doses a month from March.</p>.<p><strong>Also read: <a href="www.deccanherald.com/business/the-story-behind-the-rise-of-serum-institute-of-india-934360.html" target="_blank">The story behind the rise of Serum Institute of India</a></strong></p>.<p>Poonawalla, who runs the world’s biggest vaccine making company, tweeted, thanking Prime Minister Narendra Modi, Union Health and Family Welfare Minister Dr Harsh Vardhan and all other stakeholders including Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), the Drug Controller General of India (DCGI), Gavi, the international vaccine alliance, Gates Foundation, Astra-Zeneca and the University of Oxford.</p>.<p>The DCGI on Sunday approved Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive. The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a Covid-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/national/wait-for-vaccine-ends-serum-institute-of-india-bharat-biotech-get-dcgi-nod-for-emergency-use-934611.html" target="_blank">Wait for vaccine ends: Serum Institute of India, Bharat Biotech get DCGI nod for emergency use</a></strong></p>.<p>While for Pune-headquartered SII, India would be a priority for distribution, the company has also collaborated with Gavi and the Bill and Melinda Gates Foundation for manufacturing and delivering of up to 100 million doses of vaccines for other low and middle-income countries as part of the Gavi COVAX Advance Market Commitment (AMC).</p>
<p>With Covishield vaccine getting cleared by the government to combat the Covid-19 pandemic, Serum Institute of India (SII) CEO Adar Poonawalla said on Sunday that the risk they too has finally paid off.</p>.<p>"Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. Covishield, India's first Covid-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks," Poonawalla tweeted.</p>.<p>Last week, Poonawala had said that the company a stockpile of 40 to 50 million doses and the company will ramp up the capacity to 100 million doses a month from March.</p>.<p><strong>Also read: <a href="www.deccanherald.com/business/the-story-behind-the-rise-of-serum-institute-of-india-934360.html" target="_blank">The story behind the rise of Serum Institute of India</a></strong></p>.<p>Poonawalla, who runs the world’s biggest vaccine making company, tweeted, thanking Prime Minister Narendra Modi, Union Health and Family Welfare Minister Dr Harsh Vardhan and all other stakeholders including Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), the Drug Controller General of India (DCGI), Gavi, the international vaccine alliance, Gates Foundation, Astra-Zeneca and the University of Oxford.</p>.<p>The DCGI on Sunday approved Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive. The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a Covid-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/national/wait-for-vaccine-ends-serum-institute-of-india-bharat-biotech-get-dcgi-nod-for-emergency-use-934611.html" target="_blank">Wait for vaccine ends: Serum Institute of India, Bharat Biotech get DCGI nod for emergency use</a></strong></p>.<p>While for Pune-headquartered SII, India would be a priority for distribution, the company has also collaborated with Gavi and the Bill and Melinda Gates Foundation for manufacturing and delivering of up to 100 million doses of vaccines for other low and middle-income countries as part of the Gavi COVAX Advance Market Commitment (AMC).</p>
